Horizon Pharma Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. The company's marketed medicine portfolio consists of RAVICTI for the treatment of urea cycle disorders; PROCYSBI to treat nephropathic cystinosis; ACTIMMUNE for the treatment of chronic granulomatous disease and malignant osteopetrosis; BUPHENYL to treat urea cycle disorders; and QUINSAIR for the treatment of chronic pulmonary infections due to pseudomonas aeruginosa in cystic fibrosis patients. Its products also include KRYSTEXXA to treat chronic refractory gout; RAYOS/LODOTRA for the treatment of rheumatoid arthritis, polymyalgia rheumatic, systemic lupus erythematosus, and various other indications; PENNSAID 2% to treat pain of osteoarthritis of the knees; DUEXIS for the treatment of signs and symptoms of osteoarthritis and rheumatoid arthritis; VIMOVO to treat signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis; and MIGERGOT for the treatment of vascular headache. The company has collaboration agreement with Fox Chase Cancer Center to evaluate ACTIMMUNE in combination with PD-1/PD-L1 inhibitors in various forms of cancer; Alliance for Lupus Research to evaluate RAYOS/LODOTRA on the fatigue experienced by systemic lupus erythematosus patients; and Syneos Health, Inc. in connection with its Phase III confirmatory trial to evaluate teprotumumab for the treatment of thyroid eye disease. Horizon Pharma Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:HZNP
CUSIP44047T10
Phone011-353-1772-2100
Debt
Debt-to-Equity Ratio2.17
Current Ratio1.56
Quick Ratio1.50
Price-To-Earnings
Trailing P/E Ratio14.97
Forward P/E Ratio12.27
P/E Growth1.04
Sales & Book Value
Annual Sales$1.06 billion
Price / Sales2.76
Cash Flow$3.0571 per share
Price / Cash5.78
Book Value$6.05 per share
Price / Book2.92
Profitability
EPS (Most Recent Fiscal Year)$1.18
Net Income$-410,520,000.00
Net Margins-45.06%
Return on Equity16.97%
Return on Assets3.99%
Miscellaneous
Employees1,010
Outstanding Shares165,040,000
Horizon Pharma (NASDAQ:HZNP) Frequently Asked Questions
What is Horizon Pharma's stock symbol?
Horizon Pharma trades on the NASDAQ under the ticker symbol "HZNP."
How will Horizon Pharma's stock buyback program work?
Horizon Pharma declared that its board has initiated a stock buyback program on Sunday, June 4th 2017, which authorizes the company to repurchase 1,000% of outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to repurchase shares of its stock through open market purchases. Stock repurchase programs are generally a sign that the company's leadership believes its shares are undervalued.
How were Horizon Pharma's earnings last quarter?
Horizon Pharma PLC (NASDAQ:HZNP) announced its quarterly earnings data on Wednesday, May, 9th. The biopharmaceutical company reported $0.03 EPS for the quarter, missing the Thomson Reuters' consensus estimate of $0.11 by $0.08. The biopharmaceutical company had revenue of $223.88 million for the quarter, compared to analysts' expectations of $232.05 million. Horizon Pharma had a negative net margin of 45.06% and a positive return on equity of 16.97%. The firm's revenue was up 1.4% compared to the same quarter last year. During the same period in the previous year, the company posted $0.21 EPS. View Horizon Pharma's Earnings History.
When is Horizon Pharma's next earnings date?
What price target have analysts set for HZNP?
10 brokerages have issued 1-year price objectives for Horizon Pharma's stock. Their predictions range from $16.00 to $24.00. On average, they expect Horizon Pharma's share price to reach $19.40 in the next year. View Analyst Ratings for Horizon Pharma.
What are Wall Street analysts saying about Horizon Pharma stock?
Here are some recent quotes from research analysts about Horizon Pharma stock:
- 1. Mizuho analysts commented, "We Think Raised Guidance is Possible Once 340B Delay is Official; Reiterate Buy Rating Buy Previous Rating No Change Price (5/04) $14.24 Price Target $18.00 Previous Price Target No Change 340B Rule delay may not be entirely surprising, but still positive: The Department of Health and Human Services (HHS) proposed to further delay the effective date of the 340B drug pricing program from July 1, 2018, to July 1, 2019. Mgmt. expects an official decision on this delay within a few days or weeks after Memorial Day (May 28). Because the delay will not be finalized before Horizon’s May 9 earnings call, we think the company may not raise guidance this week, but could discuss a range of potential upside estimates on its call. The company’s current revenue guidance is $1.15B-$1.18B. We think there is some investor trepidation about seasonal weakness into the print that could improve due to this update. We reiterate our Buy rating and note our model does not yet include this upside." (5/7/2018)
- 2. According to Zacks Investment Research, "Horizon Pharma’s orphan and rheumatology business units have continued to show strong growth. We expect Krystexxa, Ravicti and Actimmune to drive further growth. The acquisition of teprotumumab has further diversified the company’s portfolio. However, revenues from primary care business units declined due to the implementation of a new commercial model where the company is contracting with pharmacy benefit managers and payers to help patients obtain access to its medicines. Moreover, in June 2017, Horizon Pharma sold the marketing rights for Procysbi and Quinsair in the Europe, the Middle East and Africa regions to Chiesi Farmaceutici S.p.A. as the company focuses on higher-return businesses. Shares of the company have outperformed the industry in the past six months. Estimates have remained stable ahead of the Q1 earnings results. The company has a mixed record of earnings surprises in recent quarters." (5/4/2018)
- 3. Cantor Fitzgerald analysts commented, "Message in a bottle/vial. The four doctors we spoke with were positive on the safety and efficacy of Horizon’s Krystexxa. One of the four doctors believed that Krystexxa was a ‘wonder’ drug and was bullish on its growth prospects. The other three doctors were more measured. They all agreed that Krystexxa is a very good drug, but were not convinced it would be widely used among rheumatologists because it works best for a small group of refractory patients. The main barrier to uptake is not anaphylaxis. There are two reasons doctors don’t widely use Krystexxa: 1) the high cost relative to standard of care; 2) because it’s an IV, while the standard of care is oral." (3/14/2018)
Who are some of Horizon Pharma's key competitors?
Some companies that are related to Horizon Pharma include Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Alnylam Pharmaceuticals (ALNY), Sarepta Therapeutics (SRPT), Nektar Therapeutics (NKTR), Genmab A/S (GNMSF), BeiGene (BGNE), Valeant Pharmaceuticals Intl (VRX), SAGE Therapeutics (SAGE), Alkermes (ALKS), Dr.Reddy's Laboratories (RDY), Agios Pharmaceuticals (AGIO), Catalent (CTLT), Loxo Oncology (LOXO) and FibroGen (FGEN).
Who are Horizon Pharma's key executives?
Horizon Pharma's management team includes the folowing people:
- Mr. Timothy P. Walbert, Chairman, Pres & CEO (Age 51)
- Mr. Paul W. Hoelscher, Exec. VP & CFO (Age 53)
- Mr. Barry J. Moze, Exec. VP & Chief Admin. Officer (Age 64)
- Ms. Irina Konstantinovsky, Exec. VP & Chief HR Officer (Age 48)
- Mr. Miles W. McHugh, Chief Accounting Officer and Sr. VP (Age 53)
Has Horizon Pharma been receiving favorable news coverage?
Media headlines about HZNP stock have been trending somewhat positive on Saturday, according to Accern Sentiment Analysis. Accern rates the sentiment of media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Horizon Pharma earned a media sentiment score of 0.25 on Accern's scale. They also assigned media headlines about the biopharmaceutical company an impact score of 45.17 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.
Who are Horizon Pharma's major shareholders?
Horizon Pharma's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Scopia Capital Management LP (9.19%), BlackRock Inc. (7.85%), Dimensional Fund Advisors LP (3.71%), venBio Select Advisor LLC (3.13%), JPMorgan Chase & Co. (2.14%) and Northern Trust Corp (1.19%). Company insiders that own Horizon Pharma stock include Brian K Beeler, Jeffrey W Sherman, Michael G Grey, Robert Carey and Timothy P Walbert. View Institutional Ownership Trends for Horizon Pharma.
Which institutional investors are selling Horizon Pharma stock?
HZNP stock was sold by a variety of institutional investors in the last quarter, including Scopia Capital Management LP, Dimensional Fund Advisors LP, BlackRock Inc., JPMorgan Chase & Co., Guggenheim Capital LLC, UBS Group AG, C WorldWide Group Holding A S and SG Americas Securities LLC. Company insiders that have sold Horizon Pharma company stock in the last year include Brian K Beeler and Timothy P Walbert. View Insider Buying and Selling for Horizon Pharma.
Which institutional investors are buying Horizon Pharma stock?
HZNP stock was purchased by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Millennium Management LLC, venBio Select Advisor LLC, American Century Companies Inc., Redwood Investments LLC, Federated Investors Inc. PA, Russell Investments Group Ltd. and Prudential Financial Inc.. View Insider Buying and Selling for Horizon Pharma.
How do I buy shares of Horizon Pharma?
Shares of HZNP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Horizon Pharma's stock price today?
One share of HZNP stock can currently be purchased for approximately $17.67.
How big of a company is Horizon Pharma?
Horizon Pharma has a market capitalization of $2.91 billion and generates $1.06 billion in revenue each year. The biopharmaceutical company earns $-410,520,000.00 in net income (profit) each year or $1.18 on an earnings per share basis. Horizon Pharma employs 1,010 workers across the globe.
How can I contact Horizon Pharma?
Horizon Pharma's mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE 1ST FLOOR, DUBLIN L2, D04 C5Y6. The biopharmaceutical company can be reached via phone at 011-353-1772-2100 or via email at [email protected]
MarketBeat Community Rating for Horizon Pharma (HZNP)
MarketBeat's community ratings are surveys of what our community members think about Horizon Pharma and other stocks. Vote "Outperform" if you believe HZNP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HZNP will underperform the S&P 500 over the long term. You may vote once every thirty days.
